FI972744A - Amino acid compositions and their use in clinical nutrition - Google Patents

Amino acid compositions and their use in clinical nutrition Download PDF

Info

Publication number
FI972744A
FI972744A FI972744A FI972744A FI972744A FI 972744 A FI972744 A FI 972744A FI 972744 A FI972744 A FI 972744A FI 972744 A FI972744 A FI 972744A FI 972744 A FI972744 A FI 972744A
Authority
FI
Finland
Prior art keywords
tnf
amino acid
diminution
levels
acid compositions
Prior art date
Application number
FI972744A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI972744A0 (en
Inventor
Heinz Schneider
Ronald G Thurman
Original Assignee
Novartis Nutrition Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08392694 external-priority patent/US5656608B1/en
Priority claimed from GBGB9512100.0A external-priority patent/GB9512100D0/en
Application filed by Novartis Nutrition Ag filed Critical Novartis Nutrition Ag
Publication of FI972744A0 publication Critical patent/FI972744A0/en
Publication of FI972744A publication Critical patent/FI972744A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pediatric Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides the use of at least one amino acid selected from the group consisting of glycine, alanine and serine, or the physiologically acceptable salts thereof, in the preparation of a medicament or nutritional formulation for the diminution of tumor necrosis factor (TNF) levels in patients in whom said levels are elevated beyond those which mediate physiological homeostasis and local inflammation. Such diminution of TNF levels can i.a. be achieved by inhibition or diminution of: (i) tumor necrosis factor (TNF) production by macrophage-type cells; (ii) the release of TNF from macrophage-type cells; and/or (iii) the binding of TNF by TNF receptors.
FI972744A 1995-02-23 1997-06-25 Amino acid compositions and their use in clinical nutrition FI972744A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08392694 US5656608B1 (en) 1995-02-23 1995-02-23 Amino acid compositions and methods of treatment using same
GBGB9512100.0A GB9512100D0 (en) 1995-06-14 1995-06-14 Improvements in or relating to organic compounds
PCT/EP1996/000739 WO1996025861A1 (en) 1995-02-23 1996-02-22 Amino acid compositions and use thereof in clinical nutrition

Publications (2)

Publication Number Publication Date
FI972744A0 FI972744A0 (en) 1997-06-25
FI972744A true FI972744A (en) 1997-08-22

Family

ID=26307213

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972744A FI972744A (en) 1995-02-23 1997-06-25 Amino acid compositions and their use in clinical nutrition

Country Status (18)

Country Link
EP (1) EP0810829B1 (en)
JP (1) JPH11501301A (en)
KR (1) KR19980702436A (en)
CN (1) CN1175887A (en)
AT (1) ATE191615T1 (en)
AU (1) AU710527B2 (en)
BR (1) BR9607336A (en)
CA (1) CA2210499A1 (en)
CZ (1) CZ266797A3 (en)
DE (1) DE69607750T2 (en)
DK (1) DK0810829T3 (en)
ES (1) ES2145997T3 (en)
FI (1) FI972744A (en)
HU (1) HUP9800049A3 (en)
NO (1) NO973884L (en)
PL (1) PL182205B1 (en)
PT (1) PT810829E (en)
WO (1) WO1996025861A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US6096785A (en) * 1996-07-30 2000-08-01 Novartis Nutrition Ag Amino acid compositions and use thereof in treating renal dysfunction
JP2000515874A (en) * 1996-07-30 2000-11-28 ノバルテイス・ニユートリシヨン・アクチエンゲゼルシヤフト Amino acid compositions and their use in treating tumor growth and metastasis
GB9701674D0 (en) * 1997-01-28 1997-03-19 Novartis Nutrition Ag Use of organic compounds
EP0882451B1 (en) * 1997-06-05 2004-05-12 Novartis Nutrition AG Glycine for prevention or treatment of transplant rejection
US6310097B1 (en) * 1997-07-28 2001-10-30 Riken Protecting and survival promoting agent for central nervous cell
US6143786A (en) * 1999-02-02 2000-11-07 Novartis Nutrition Ag Oral arginine and insulin secretion
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL
NL1019368C2 (en) 2001-11-14 2003-05-20 Nutricia Nv Preparation for improving receptor performance.
DE10257360A1 (en) * 2002-12-09 2004-07-08 Fresenius Kabi Deutschland Gmbh Gastrointestinally administrable formulation and its use
EP1665940A4 (en) 2003-09-02 2011-01-19 Bbk Bio Corp Diet food
EP1591118A1 (en) 2004-04-27 2005-11-02 Nutri-Fit GmbH & Co. KG Use of melatonin in preventing postoperative complications
KR100555904B1 (en) * 2004-05-19 2006-03-03 주식회사 오스코텍 A herbal mixture extract of Pleurotus eryngii and Acanthopanacis Cortex and composition comprising the same for prevention and treatment of osteoporosis
EP2032170B1 (en) * 2006-06-14 2012-11-28 N.V. Nutricia Anti-inflammatory composition comprising glycine and lactoferrin and the use thereof
JP5979816B2 (en) 2008-01-04 2016-08-31 ネステク ソシエテ アノニム Compositions containing unsaturated fatty acids and nitric oxide releasing compounds and their use to enhance cognitive function and related functions
US20100179089A1 (en) * 2009-01-13 2010-07-15 Deutz Nicolaas E P Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly
NZ615091A (en) * 2009-06-08 2015-03-27 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
KR101213825B1 (en) * 2010-07-16 2012-12-18 서울대학교산학협력단 Composition for the prevention and treatment of fatty liver diseases containing serine as an active ingredient
KR101758424B1 (en) 2010-09-24 2017-07-14 유니버시티 오브 플로리다 리서치 파운데이션, 인크. Materials and methods for improving gastrointestinal function
JP6378307B2 (en) 2013-03-11 2018-08-22 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Substances and methods for improving lung function and for preventing and / or treating radiation-induced lung complications
BR112017010832A2 (en) 2014-11-24 2017-12-26 Entrinsic Health Solutions Llc amino acid compositions for treating disease symptoms
EP3355878A1 (en) 2015-10-02 2018-08-08 N.V. Nutricia Glycine for use in tolerance induction in allergic patients
FR3041882B1 (en) * 2015-10-06 2019-04-12 Universite D'angers PHARMACEUTICAL PREPARATION FOR THE PREVENTIVE TREATMENT OF LESIONS D'ISCHENIE REPERFUSION
MX2019003821A (en) 2016-10-04 2019-12-18 Univ Florida Amino acid compositions and uses thereof.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2591893B1 (en) * 1985-12-19 1988-11-10 Centre Nat Rech Scient METHIONINE-DEFECTED NUTRITIONAL COMPOSITIONS FOR INHIBITING THE DEVELOPMENT AND DISSEMINATION OF MALIGNANT TUMORS IN MAMMALS
US4988724A (en) * 1988-12-09 1991-01-29 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
ATE174794T1 (en) * 1991-09-27 1999-01-15 Univ Texas PREPARATIONS CONTAINING AMINO ACIDS FOR PARENTERAL APPLICATION TO COMBAT HYPOTENSION AND RELATED PATHOLOGIES
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease

Also Published As

Publication number Publication date
JPH11501301A (en) 1999-02-02
DK0810829T3 (en) 2000-08-28
HUP9800049A2 (en) 1998-05-28
DE69607750T2 (en) 2000-08-31
FI972744A0 (en) 1997-06-25
EP0810829A1 (en) 1997-12-10
ES2145997T3 (en) 2000-07-16
MX9706140A (en) 1997-11-29
PL182205B1 (en) 2001-11-30
HUP9800049A3 (en) 1999-01-28
NO973884L (en) 1997-10-17
AU710527B2 (en) 1999-09-23
PL321238A1 (en) 1997-11-24
ATE191615T1 (en) 2000-04-15
CA2210499A1 (en) 1996-08-29
NO973884D0 (en) 1997-08-22
DE69607750D1 (en) 2000-05-18
WO1996025861A1 (en) 1996-08-29
KR19980702436A (en) 1998-07-15
AU4879596A (en) 1996-09-11
EP0810829B1 (en) 2000-04-12
CN1175887A (en) 1998-03-11
PT810829E (en) 2000-08-31
BR9607336A (en) 1997-11-25
CZ266797A3 (en) 1998-03-18

Similar Documents

Publication Publication Date Title
FI972744A (en) Amino acid compositions and their use in clinical nutrition
IL141021A (en) Use of a polypeptide related to copolymer 1 for preparing a medicament for treating autoimmune diseases
BG103335A (en) Application of fumaric acid derivatives
TR199701071T2 (en) Compounds and compositions for delivery of the active substance.
MX9605940A (en) Bio-aromatic compounds carrying an adamantyl group in ortho, pharmaceutical and cosmetic compositions containing them and utilization.
ATE261308T1 (en) DEXTRAN FORMULATIONS FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASES
IL112111A (en) Peptides having growth hormone releasing properties and pharmaceutical compositions containing them
WO2006023665A3 (en) Il-1 antagonist formulations
GB9806632D0 (en) Peptide factor
EP0797999A3 (en) Formulations of obesity protein
MXPA02012064A (en) Macromolecular drug complexes and compositions containing the same.
EP0825197A3 (en) New 6-hydroxy and 6-oxo-anstro-stane derivatives active on the cardiovascular system and pharmaceutical compositions containing same
DK0981362T3 (en) Use of GLP-2 agonists to improve the function of the upper gastrointestinal tract
ATE549036T1 (en) THYMOSINE ALPHA-1 PEPTIDE/POLYMER CONJUGATES
EP1285660A4 (en) Zinc-supplementary compositions for oral administration
TR200101163T2 (en) Bile water substituted phenyl-alkenoylguanidines, production methods, uses
Wildburger et al. Comparison of the values of basic fibroblast growth factor determined by an immunoassay in the sera of patients with traumatic brain injury and enhanced osteogenesis and the effects of the same sera on the fibroblast growth in vitro
JPS62501705A (en) Proglumide-containing pharmaceutical composition for use in treating neoplastic diseases
EP0821969A3 (en) Medicinal Composition comprising TCF-II
BR0109279A (en) Lhrh antagonists, their preparation and application as a medicine
NZ336043A (en) Use of COMT inhibitors for preventing diabetic vascular dysfunctions or neuropathy
DK521389A (en) PREPARATION FOR THE TREATMENT OF ADDRENOLEUCODYSTROPHY
DE69804674T2 (en) LIPOSOMES WITH MULTIPLE BRANCHED PEPTIDE CONSTRUCTIONS FOR USE AGAINST HIV
Wang et al. Effects of arginine-devoid diets in chronically uremic rats
WO2001039725A3 (en) Drug preparations